{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T12:04:39Z","timestamp":1726920279771},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,16]]},"DOI":"10.7759\/cureus.52374","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T15:15:47Z","timestamp":1705418147000},"source":"Crossref","is-referenced-by-count":1,"title":["Use of Tocilizumab Followed by Rituximab Desensitization on Relapsing Myelin Oligodendrocyte Antibody Disease: A Case Report"],"prefix":"10.7759","author":[{"given":"Kelsey C","family":"Dayrit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn O","family":"Chua-Ley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1488","article-title":"Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein","volume":"13","author":"O'Connor KC","year":"2007","unstructured":"O'Connor KC, McLaughlin KA, De Jager PL, et al.. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med. 2007, 13:211-7. 10.1038\/nm1488","journal-title":"Nat Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-323158","article-title":"Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK","volume":"91","author":"O'Connell K","year":"2020","unstructured":"O'Connell K, Hamilton-Shield A, Woodhall M, et al.. Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK. J Neurol Neurosurg Psychiatry. 2020, 91:1126-8. 10.1136\/jnnp-2020-323158","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/1352458519845112","article-title":"The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults","volume":"26","author":"de Mol CL","year":"2020","unstructured":"de Mol CL, Wong Y, van Pelt ED, et al.. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler. 2020, 26:806-14. 10.1177\/1352458519845112","journal-title":"Mult Scler"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk M","year":"2017","unstructured":"Jurynczyk M, Messina S, Woodhall MR, et al.. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017, 140:3128-38. 10.1093\/brain\/awx276","journal-title":"Brain"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan S","year":"2018","unstructured":"Ramanathan S, Mohammad S, Tantsis E, et al.. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2018, 89:127-37. 10.1136\/jnnp-2017-316880","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25909","article-title":"Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"89","author":"Cobo-Calvo A","year":"2021","unstructured":"Cobo-Calvo A, Ruiz A, Rollot F, et al.. Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease. Ann Neurol. 2021, 89:30-41. 10.1002\/ana.25909","journal-title":"Ann Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102251","article-title":"Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients","volume":"44","author":"Whittam DH","year":"2020","unstructured":"Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, et al.. Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. Mult Scler Relat Disord. 2020, 44:102251. 10.1016\/j.msard.2020.102251","journal-title":"Mult Scler Relat Disord"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.572863","article-title":"Rituximab hypersensitivity: from clinical presentation to management","volume":"11","author":"Fouda GE","year":"2020","unstructured":"Fouda GE, Bavbek S. Rituximab hypersensitivity: from clinical presentation to management. Front Pharmacol. 2020, 11:572863. 10.3389\/fphar.2020.572863","journal-title":"Front Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001100","article-title":"Interleukin-6 receptor blockade in treatment-refractory MOG-IgG-associated disease and neuromyelitis optica spectrum disorders","volume":"9","author":"Ringelstein M","year":"2022","unstructured":"Ringelstein M, Ayzenberg I, Lindenblatt G, et al.. Interleukin-6 receptor blockade in treatment-refractory MOG-IgG-associated disease and neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2022, 9:e1100. 10.1212\/NXI.0000000000001100","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/222379-use-of-tocilizumab-followed-by-rituximab-desensitization-on-relapsing-myelin-oligodendrocyte-antibody-disease-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:13:09Z","timestamp":1707509589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/222379-use-of-tocilizumab-followed-by-rituximab-desensitization-on-relapsing-myelin-oligodendrocyte-antibody-disease-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.52374","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,16]]}}}